Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

Abstract Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequential treatment with MKIs is conducted in Japanese clinical practice is unknown. Methods This retrospective observational cohort study used a J...

Full description

Bibliographic Details
Main Authors: Chie Masaki, Kiminori Sugino, Yoshinori Tanizawa, Kenichi Nakamura, Yui Okada, Zhihong Cai, Takahiro Okamoto
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-12-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-022-00346-y

Internet

https://doi.org/10.1007/s40801-022-00346-y

Similar Items